Co-Diagnostics Inc (NASDAQ:CODX) announced Wednesday it has received new orders for its vector control tests and equipment from mosquito abatement districts after participating in several vector control conferences.
Recent conference appearances included a presentation at the 3rd International Conference on Zika Virus and Aedes Related Infections on February 13-16 in Washington, DC where Co-Diagnostics was well-received by the global audience.
The conference provided a forum for the company to showcase its technology platform and a full suite of mosquito abatement tests to those in attendance, and to report on its rapid response to the outbreak of Covid-19 during the conference’s coronavirus symposia.
Co-Diagnostics has recently added new mosquito abatement customers in the eastern US as well as the midwest. The company offers tests tailored to all regions of the country, including multiplexed tests that include either eastern equine encephalitis or western equine encephalitis, depending on the abatement district location.
As a result of the conference presentation and exhibition, the company said it received broad domestic and international interest in its products.
“Our company strategy focuses on leveraging our patented CoPrimer platform for applications in plant, animal, and human genomes,” said CEO Dwight Egan.
“We are now generating sales in all of these verticals, which include revenue from well-respected customers and partners like LGC, Dare Labs, Biotech Bolivia, Guyana Defense Force, numerous mosquito abatement districts and a significant joint venture in India with 5 tests cleared with the CDSCO for use as in-vitro diagnostics (IVD’s)."
Egan continued: “We continue to receive overwhelming interest in the progress of our coronavirus product offering. In addition to fulfilling a substantial initial order of the Research Use Only version of this test for an international customer, we also are quickly moving towards obtaining clearance from the relevant regulatory bodies that we believe will soon allow us to market and sell the test as a fully-approved IVD.”
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham